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Photorefractive keratectomy (PRK) represents a therapeutic option to remodel corneal stroma and to compensate refractive errors,
which involves inflammatory and/or regenerative processes. In this context, the modulation of cytokines/chemokines in the
conjunctival sac fluid and their role in themaintenance of the cornealmicroenvironment during the healing process upon refractive
procedures has not been deeply investigated. In this study, serial samples of conjunctival sac fluid of patients (𝑛 = 25) undergoing
PRKwere harvested before and at different time points after surgery.The levels of 29 cytokines/chemokines/growth factors involved
in inflammatory/immune processes were measured with a multiplex array system.The results have firstly highlighted the different
pattern of cytokine expression between the microenvironment at the anterior surface of the eye and the systemic circulation. More
importantly, the kinetic of modulation of cytokines/chemokines at the conjunctival level following PRK revealed that while the
majority of cytokines/chemokines showed a significant decrease,MCP-1 emerged in light of its pronounced and significant increase
soon after PRK and during the follow-up. This methodological approach has highlighted the role of MCP-1 in the healing process
following PRK and has shown a potential for the identification of expression/modulation of soluble factors for biomarker profiling
in ocular surface diseases.
1. Introduction
The generation and preservation of the microenvironment
of the tear film is guaranteed by the biological interplay
between the ocular surface together with the related glands
and local neural interconnections, that represent the core
players for the protection of the transparency of the cornea
and the health of the ocular surface [1]. In particular, the
tear layer can be considered a reservoir of soluble factors
with biological effects involved in the maintenance of the
physiology of surface epithelial cells including protective and
antimicrobial activities, nourishing functions, and contribu-
tion to local wound healing/anti-inflammatory responses [2–
4]. In normal conditions, it has been demonstrated that tears
of healthy subjects are characterized by a so-called “immune
tone” generated by local levels of cytokines and chemokines
released by different cell types, such as immune cells and
epithelial cells [5, 6]. Therefore, any alteration of the tear film
may have direct consequences on the ocular surface integrity
leading to pathological condition such as dry eye [7, 8].
However, at the same time, any changes on the composition
of the conjunctival sac fluid might have a potential as clinical
biomarker to monitor the onset-evolution of ocular surface
diseases [9–11] and the response to pharmacological and/or
surgical interventions [12–14].
Photorefractive keratectomy (PRK) is one of the most
commonly used surgical techniques to correct refractive
errors through a laser-induction ablation of the corneal
epithelium, which is able to induce corneal stromal remod-
elling with changes in corneal refraction [15]. This procedure
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is followed by the release of several factors including
cytokines, growth factors, and matrix metalloproteases that
are involved in both corneal wound healing process and
possible postoperative (inflammatory) complications [16]. In
this light, PRKmight be considered amodel of corneal regen-
eration for studies aiming at improving the comprehension of
the complex biological processes underlying themaintenance
of local corneal microenvironment and the wound healing
process.
Therefore, the objective of this study was to monitor
the local cytokines/chemokines levels in patients undergoing
PRK including awide inflammatory/immunemediators’ pro-
file. By this experimental approach, we aimed (i) to increase
the understanding of the physiopathological response after
PRK in a long term postoperative period; (ii) to identify
molecular mediators involved in the wound healing process
after PRK; and (iii) to assess a methodological approach
for the identification of molecular mediators that could act
as laboratory biomarkers for prognostic and monitoring
purposes in the context of ocular surface diseases.
2. Materials and Methods
2.1. Patients’ Population andConjunctival Sac Fluid Collection.
The subjects involved in the study included 25 patients
enrolled by the Ophthalmology Section at the University-
Hospital of Ferrara. All patients underwent complete pre-
operatively ophthalmic examination before receiving myopic
PRK treatment by using the 200Hz Allegretto laser platform
(Wavelight Laser Technologie AG, Erlangen, Germany). In
particular, preoperative (1 day before PRK), as well as post-
operative (2, 5, and 30 days after PRK), follow-up examina-
tions included analyses of uncorrected distance visual acuity
(UDVA), corrected distance visual acuity (CDVA), manifest
refraction, corneal topography, and complications. Before
and after PRK, at the time of patients’ clinical assessment,
conjunctival sac fluid samples were collected by using stan-
dard strips of Schirmer test as previously described [17].
Briefly, for each subject a volume corresponding to three
notches of the stripwas collected. Stripswere then transferred
in 400𝜇L of 0.9% NaCl solution at 4∘C for 36 hours, to
allow the release of the conjunctival sac fluid proteins from
the strip in the solution. As control, conjunctival sac fluid
samples were also collected from the normal contralateral
eye of the 52% of enrolled patients. Aliquots of conjunctival
sac fluid solutions were stored at −80∘C and thawed only
once before analyses. Forearm blood samples were collected
from healthy subjects in the presence of sodium citrate and
immediately centrifuged for plasma isolation that were stored
at −80∘C in single-use aliquots. Written informed consents
were obtained from each patient and all the procedures
that followed were in accordance with the Declaration of
Helsinki and were approved by the institutional review board
(University Hospital of Ferrara).
2.2. Analysis of Cytokines and Chemokines. The biological
samples were frozen and thawed only once before performing
the MILLIPLEX MAP Human Cytokine/Chemokine Panel
(Merck Millipore, Billerica, MA), a bead-based multiplex
immunoassay, which allows the simultaneous quantification
of the following 29 human cytokines: EGF, IL-1𝛽, IL-1
receptor antagonist (RA), IL-1𝛼, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, 1L-17A,
EOTAXIN, G-CSF, GM-CSF, IFN-𝛼2, IFN-𝛾, CXCL10, MCP-
1, MIP-1𝛼, MIP-1𝛽, TNF-𝛼, TNF-𝛽, and VEGF. Samples were
analysed in duplicate following the manufacturer’s recom-
mended protocols and the results were read on a MAGPIX
instrument equipped with the MILLIPLEX-Analyst Software
using a five-parameter nonlinear regression formula to com-
pute sample concentrations from the standard curves, as
previously described [18].
2.3. Network Analysis. The identified proteins were analysed
by using the IPA software (http://www.ingenuity.com/; Inge-
nuity Systems, Redwood City, CA, USA) in order to identify
biological functions and molecular pathways associating
the proteins, as well as predict protein-protein interaction
networks determined by the Ingenuity Knowledge Base [19].
Briefly, the Ingenuity Pathway Knowledge Base identifies
protein networks that are ranked in relation to the biological
functions assigned to the network. The score indicates the
probability that eligible proteins are in the network by
random chance. In other words, high-score values indicate
high reliability of protein association (a score > 2 is con-
sidered to be significant). The most highly scored networks
identifiedwere then graphically visualized showing themajor
molecular relationship between proteins.
2.4. Statistical Analysis. Data were analysed by SPSS statis-
tical software and calculated as median, mean ± standard
deviation (SD) for each group of data obtained from samples
analysis. Box plots were used to show the median values
and 25th to 75th percentiles. Differences between values were
evaluated by using a pairwise sign-rankWilcoxon’s test and a
𝑝 value < 0.05 was considered statistically significant.
3. Results
3.1. Study Population and Clinical Assessment. The cohort of
patients enrolled for this study consisted of 64% of females
with age ranging between 24 and 48 years and a mean
age of 36.1 years and of 36% of males characterized by
age ranging between 22 and 54 years with a mean age of
36.7 years. After PRK treatment the postoperative course
was clinically monitored: no complications such as keratitis,
infections and/or delay on corneal epithelium regeneration
were reported and all patients showed full correction of the
refractive errors and restoration of a proper visual quality,
with the exception of one patient showing hypermetropy at
the last clinical follow-up assessment performed 30 days after
surgical intervention.
3.2. Expression Profile of Cytokines and Chemokines in the
Conjunctival Sac Fluid. In a preliminary experiment, we have
analysed the levels of expression of 29 cytokines/chemokines
in the conjunctival sac fluid samples collected from the
normal contralateral eyes of patients (see Figure 1(a)
and Supplementary Table 1 in Supplementary Material
Mediators of Inflammation 3
ND
EGF
IL-1RA
MCP-1
IP-10
IL-3
IL-17A
G-CSF
IFN-𝛼2
IL-13
IL-7
IL-8
VEGF Eotaxin IL-2
GM-CSF IL-4
IFN-𝛾 IL-5
IL-10 IL-6
MIP-1𝛼
MIP-1𝛽
IL-15 TNF-𝛼
IL-1𝛼 TNF-𝛽
IL-1𝛽
Range: 10–50pg/mL
Range: 50–1000 pg/mL
Range: over 1000 pg/mLRange: up to 10pg/mL
IL-12(p70)
IL-12(p40)
(a)
G-CSF
EGF IP-10
VEGF
MCP-1 Eotaxin
GM-CSF
IL-8
IL-7
IL-1RA
IL-12(p70)
IL-10
IL-17A IL-6
IL-15 IL-5
IL-13 IL-4
IL-3IL-12(p40)
IFN-𝛼2
IFN-𝛾
MIP-1𝛼
MIP-1𝛽
TNF-𝛼
TNF-𝛽IL-1𝛼
IL-1𝛽
IL-2
ND
Range: 10–50pg/mL
Range: 50–1000 pg/mL
Range: over 1000 pg/mLRange: up to 10pg/mL
(b)
Figure 1: Comparison between local (microenvironment of the anterior surface of the eye) and systemic levels of cytokines/chemokines in
healthy subjects. The levels of 29 cytokines/chemokines were measured by multiples assays in conjunctival sac fluid samples collected from
normal contralateral eyes of patients (normal controls) (a) and serum samples (b) of healthy subjects. The levels of expression have been
arbitrarily divided in ranges, as detailed in the legend, and graphically represented based on the number of cytokines/chemokines belonging
to the different clusters. ND: not detectable.
available online at http://dx.doi.org/10.1155/2015/942948).
In particular, as summarized in Figure 1(a), among the 29
cytokines/chemokines analysed by multiplex assay, only
IL-3 and IL-17A were undetectable in all samples while
the following 27 cytokines/chemokines were detectable
at different levels (up to over 1000 pg/mL): EGF, IL-1RA,
MCP-1, IP-10/CXCL10, Eotaxin, GM-CSF, IFN-𝛾, IL-10,
IL-12(p40), IL-12(p70), IL-15, IL-1𝛼, IL-1𝛽, IL-2, IL-4, IL-5,
IL-6, MIP-1𝛼, MIP-1𝛽, TNF-𝛼, TNF-𝛽, IFN-𝛼2, G-CSF,
IL-13, IL-7, IL-8, and VEGF. Notably, the expression profile
and the levels assessed in the conjunctival sac fluids were
significantly different from those documented in serum
samples of healthy subjects (Figure 1(b) and Supplementary
Table 1). In fact, a higher number of soluble factors were
undetectable at the serum level: IL-10, IL-12(p40), IL-15,
IL-13, IL-17A, IL-1𝛼, IL-1𝛽, IL-2, IL-3, IL-4, IL-5, IL-6, and
TNF-𝛽 (Figure 1(b)). Moreover, when clustered for ranges of
expression levels, a limited number of cytokines/chemokines
were detected at serum levels higher than 50 pg/mL and
no soluble factor showed systemic levels over 1000 pg/mL
(Figures 1(a)-1(b)).
3.3. Differential Modulation of Cytokines/Chemokines in the
Conjunctival Sac Fluid following PRKTreatment. Thepatients
enrolled in the study underwent PRK surgery and the levels
of the same 29 cytokines/chemokines were evaluated in serial
samples of conjunctival sac fluid collected one day before
and at different time points (days 2, 5, and 30) after PRK.
The levels of the cytokines and chemokines assessed before
and after the PRK surgery are reported in Table 1. In order to
identify clusters of cytokines/chemokines that might poten-
tially be linked and interact at the conjunctival microen-
vironment level, we have firstly analysed the kinetics of
release of the different cytokines/chemokines (Table 1).Then,
in order to understand the potential association among the
cytokines/chemokines having in common the same kinetic
profile, the data were analysed using Ingenuity Pathway
Analysis (IPA) software (http://www.ingenuity.com/) which
identifies relevant interactions and biological mechanisms
among proteins (Supplementary Table 2).
Based on these analyses, we have identified two dif-
ferent kinetics of modulation, referred to as Profile I and
Profile II. In particular, as detailed in Table 1, the majority
of the cytokines/chemokines analysed, including EGF, IP-
10/CXCL10, Eotaxin, GM-CSF, IFN-𝛾, IL-10, IL-12(p40), IL-
12(p70), IL-15, G-CSF, IL-1𝛼, IL-2, IL-4, IL-5, MIP-1𝛼, MIP-
1𝛽, TNF-𝛼, TNF-𝛽, IFN-𝛼2, IL-1RA, IL-13, IL-7, and VEGF,
showed a dramatic decrease at day 2 after PRK, followed
by a rapid recover at day 5 and thereafter (Profile I). The
kinetics of modulation of EGF, G-CSF, and IL-1RA are shown
in Figure 2(a) as representative of Profile I. Within the 23
cytokines/chemokines of Profile I, two networks were found
with score >2 and involving 12 and 10 proteins, respectively
(Figure 2(b)). Of interest, both of these networks involve a
high number of focus molecules mainly related to immune
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Table 1: Cytokines and chemokines levels in conjunctival sac fluid of patients undergoing PRK.
Cytokines and chemokines 1 day before PRK (pg/mL)a Follow-up after PRK
2 days (pg/mL)a 5 days (pg/mL)a 30 days (pg/mL)a
EGF Epidermal growthfactor 68.7 (82.4 ± 52.3) 13.8 (25.0 ± 38.7) 76.7 (88.7 ± 65.6) 80.2 (95.2 ± 58.0)
Eotaxin C-C motif chemokineligand 11 0.0 (2.4 ± 4.8) 0.0 (0.8 ± 2.8) 6.4 (6.7 ± 7.0) 8.5 (7.1 ± 5.8)
G-CSF
Granulocyte
colony-stimulating
factor
31.5 (41.3 ± 27.0) 12.8 (15.4 ± 16.2) 26.1 (32.9 ± 24.4) 46.8 (52.7 ± 27.4)
GM-CSF
Granulocyte-
macrophage
colony-stimulating
factor
0.7 (0.9 ± 0.7) 0.0 (0.4 ± 0.6) 1.1 (1.4 ± 0.8) 1.6 (1.4 ± 0.6)
IFN-𝛼2 Interferon, alpha2 38.2 (47.0 ± 26.7) 23.7 (27.1 ± 19.9) 33.3 (33.7 ± 19.1) 44.4 (46.9 ± 24.6)
IFN-𝛾 Interferon, gamma 2.1 (3.3 ± 4.6) 0.0 (0.8 ± 0.9) 2.6 (2.8 ± 1.5) 2.7 (2.8 ± 1.2)
IL-10 Interleukin 10 1.3 (1.8 ± 1.0) 0.8 (0.7 ± 0.7) 1.6 (1.8 ± 1.1) 2.2 (2.3 ± 0.9)
IL-12(p40) Interleukin 12 subunitp40 3.6 (3.3 ± 2.7) 2.8 (2.1 ± 2.3) 4.5 (4.1 ± 3.1) 5.1 (5.1 ± 3.6)
IL-12(p70) Interleukin 12complex 2.5 (2.5 ± 2.1) 0.0 (0.6 ± 1.2) 3.4 (3.2 ± 2.3) 3.9 (3.6 ± 2.2)
IL-13 Interleukin 13 14.3 (19.2 ± 14.1) 3.0 (5.2 ± 8.0) 14.6 (17.6 ± 13.3) 26.9 (29.9 ± 17.0)
IL-15 Interleukin 15 1.3 (1.2 ± 1.1) 0.0 (0.4 ± 0.7) 2.1 (1.9 ± 1.4) 2.1 (2.2 ± 1.2)
IL-17A Interleukin 17 OOR< OOR< OOR< OOR<
IL-1RA Interleukin 1 receptorantagonist 562.0 (703.7 ± 562.5) 95.1 (141.5 ± 152.9) 498.0 (663.8 ± 579.5) 895.3 (920.4 ± 550.8)
IL-1𝛼 Interleukin 1, alpha 11.0 (11.2 ± 5.1) 6.7 (8.4 ± 6.0) 13.5 (14.8 ± 6.5) 16.9 (19.0 ± 8.2)
IL-1𝛽 Interleukin 1, beta 0.7 (0.7 ± 0.8) 0.7 (0.8 ± 1.0) 1.4 (1.4 ± 1.0) 1.6 (1.9 ± 1.1)
IL-2 Interleukin 2 0.0 (0.5 ± 0.7) 0.0 (0.2 ± 0.4) 0.7 (0.7 ± 0.6) 0.9 (0.9 ± 0.6)
IL-3 Interleukin 3 OOR< OOR< OOR< OOR<
IL-4 Interleukin 4 5.25 (16.1 ± 36.7) 0.0 (4.7 ± 10.83) 3.6 (8.1 ± 15.3) 8.7 (12.1 ± 8.8)
IL-5 Interleukin 5 1.2 (2.7 ± 3.0) 0.0 (0.4 ± 1.3) 1.02 (1.9 ± 2.4) 2.4 (3.4 ± 3.2)
IL-6 Interleukin 6 2.4 (3.1 ± 2.4) 7.5 (9.9 ± 10.4) 2.9 (4.6 ± 5.5) 3.1 (3.5 ± 3.3)
IL-7 Interleukin 7 13.7 (16.1 ± 7.8) 4.9 (7.1 ± 8.6) 13.7 (16.9 ± 11.3) 24.8 (24.6 ± 11.0)
IL-8 Interleukin 8 22.3 (29.9 ± 18.2) 24.5 (38.8 ± 30.9) 21.3 (38.4 ± 35.2) 20.3 (30.2 ± 18.2)
IP-10 CXCL10 1432.0 (2026.6 ± 1896.5) 185.0 (435.0 ± 538.8) 2428.0 (3241.1 ± 2564.3) 2856.5 (3303.1 ± 1751.1)
MCP-1 CCL2 34.9 (83.4 ± 103.3) 80.0 (138.9 ± 104.1) 150.9 (144.2 ± 130.0) 115.9 (162.7 ± 128.5)
MIP-1𝛼 CCL3 0.0 (2.3 ± 3.5) 0.0 (1.1 ± 2.1) 5.2 (4.0 ± 4.3) 5.2 (5.0 ± 4.4)
MIP-1𝛽 CCL4 3.6 (4.5 ± 2.7) 1.3 (1.7 ± 1.8) 6.2 (5.7 ± 3.7) 5.6 (6.3 ± 3.2)
TNF-𝛼 Tumor necrosisfactor, alpha 0.0 (0.3 ± 0.6) 0.0 (0.0 ± 0.1) 0.7 (0.9 ± 1.3) 0.8 (0.7 ± 0.5)
TNF-𝛽 Tumor necrosisfactor, beta 0.0 (0.4 ± 0.8) 0.0 (0.1 ± 0.4) 0.0 (0.6 ± 0.9) 0.0 (0.7 ± 0.9)
VEGF Vascular endothelialgrowth factor 29.1 (31.9 ± 17.4) 8.7 (12.2 ± 11.7) 29.1 (42.8 ± 50.9) 52.6 (52.8 ± 21.8)
aValues are expressed as median (mean ± SD); OOR<: out (below) of detection range.
cell trafficking, cellular growth/proliferation, and inflamma-
tory responses (Supplementary Table 2).
On the other hand, IL-6, IL-8, andMCP-1 showed a differ-
ent profile of expression (Profile II) with respect to themajor-
ity of the cytokines/chemokines analysed, characterized by an
increase at day 2 after PRK (Table 1 and Figure 3(a)). These
proteins are functionally involved in a network related to
inflammatory processes (Figure 3(b)). Anyhow, among the
panel of 29 cytokines/chemokines assessed in the present
study, the peculiar kinetic of expression/modulation ofMCP-
1 characterized by a significant (𝑝 < 0.05) and persistent
increase at all times (up to 30 days) after PRK (Figure 3(a))
is certainly of note. Moreover, analysis of patient’s matched
samples shows that the levels of MCP-1 measured at the last
Mediators of Inflammation 5
1 day
Before surgery
2 days 5 days 30 days
After surgery
1 day
Before surgery
2 days 5 days 30 days
After surgery
1 day
Before surgery
2 days 5 days 30 days
After surgery
∗
∗
∗EG
F 
le
ve
ls 
(p
g/
m
L)
0
40
80
120
160
200
G
-C
SF
 le
ve
ls 
(p
g/
m
L)
0
20
40
60
80
100
IL
-1
RA
 le
ve
ls 
(p
g/
m
L)
0
400
800
1,200
1,600
2,000
(a)
Network 1 Network 2
IFN-𝛾
IFN-𝛾CXCL10
IL-10
G-CSF
IL-12 (complex)
GM-CSF
IL-4
Eotaxin
CCL11
MIP-1𝛽
MIP-1𝛼
Interferon alpha
IL-15
IL-12(p40)
GM-CSF
IL-5
IL-7
IL-2
IL-13
IL-1RA
Lymphotoxin-
TNF
alpha1-beta2
VEGF
VEGF-A
EGFIL-1𝛼
IFN-𝛽
Cytokine/chemokine growth factor
Group/complex
Direct/indirect relationship
Cytokine/chemokine growth factor
Group/complex
Direct/indirect relationship
(b)
Figure 2: Characterization of Profile I kinetics of modulation of cytokines/chemokines in the conjunctival sac fluid of patients undergoing
PRK treatment. The local levels of cytokines/chemokines were measured in conjunctival sac fluid samples collected from patients before and
at the indicated time points after PRK. In (a), modulation of EGF, G-CSF, and IL-1RA is shown as representative of Profile I. Horizontal bars
are median, upper and lower edges of box are 75th and 25th percentiles, and lines extending from box are 10th and 90th percentiles. Asterisks,
∗
𝑝 < 0.001 compared to the values before PRK. In (b), the identified panel of cytokines/chemokines sharing Profile I kinetics of modulation
was assessed for network analysis.The twomost highly scored networks are shown.The links between the different proteins generated by IPA
(ingenuity pathway analysis) are graphically illustrated and the key for the nodes and the lines are reported on the legend.
clinical follow-up assessment performed 30 days after PRK
were significantly (𝑝 < 0.05) different from the levels ofMCP-
1 detected in paired normal contralateral eyes (Figure 3(c)).
4. Discussion
Thefirst observation derived fromour study is that the profile
of expression of cytokines/chemokines at the conjunctival sac
fluid level does not match the systemic profile for the great
majority of the cytokines/chemokines analysed in line with
previous observations [11]. In this respect, we are aware that
the procedures for the measurements of the cytokines and
chemokines in tears show some difficulties and that the pro-
cedure employed to measure soluble cytokines/chemokines
in conjunctival sac fluid might underestimate the real con-
centrations (since a percentage of the proteins could remain
trapped in Schirmer strips). In spite of these potential techni-
cal limitations, the comparative analysis of the concentrations
of the same cytokines/chemokines between serum samples
and tears shows a more complex pattern of expression and
higher levels of cytokines/chemokines in the microenviron-
ment of the anterior surface of the eye, with respect to
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Figure 3: Characterization of Profile II kinetic of modulation of cytokines/chemokines in the conjunctival sac fluid of patients undergoing
PRK treatment. The local levels of cytokines/chemokines were measured in conjunctival sac fluid samples collected from patients before
and at the indicated time points after PRK. In (a), modulation of IL-6/8 and MCP-1 is shown. Horizontal bars are median, upper and lower
edges of box are 75th and 25th percentiles, and lines extending from box are 10th and 90th percentiles. Asterisk, 𝑝 < 0.05 compared to the
values before PRK. In (b), the identified panel of cytokines/chemokines sharing Profile II was assessed for network analysis and the resulting
networks are shown. The links between the different proteins generated by IPA (ingenuity pathway analysis) are graphically illustrated and
the key for the nodes and the lines are reported on the figure legend. In (c), the levels of MCP-1 were assessed in the conjunctival sac fluid of
patients 30 days after PRK and in their contralateral normal control eye. Results are reported as means ± SD, ∗𝑝 < 0.05.
the systemic circulation. This observation is likely the results
of the synthesis/release from different cellular source, such
as epithelial cells and immune cells, which might contribute
to generate the observed differences between serum and
tears.
Moreover, we report for the first time the pattern
of expression/modulation of a wide panel of cytokines/
chemokines in the conjunctival sac fluid of patients before
and after PRK treatment. As observed in a previous study
focused on the analysis of a single cytokine (TRAIL)
[17], involved in migration [20, 21] and inflammatory
[22] processes, we found that the large majority of the
cytokines/chemokines investigated in this study were char-
acterized by a drastic decrease at day 2 after surgery, followed
by a recover thereafter. Interestingly, only three cytokines
(MCP-1, IL-6, and IL-8) did not show any significant decrease
after surgery, with MCP-1 exhibiting the most remarkable
pattern. Indeed, the MCP-1 levels in the conjunctival sac
fluid showed a pronounced and significant increase already
at day 2, peaking at day 5 after surgery and maintaining high
levels up to day 30 after surgery. This pattern is particularly
noteworthy, as MCP-1 has been involved in wound healing
processes [23–27]. Therefore, it is likely that MCP-1 elevation
plays a significant role in the process of reepithelialization of
the cornea.
In conclusion, in the context of PRK, our data contribute
to identify the key inflammatory/immunemediators involved
in the local physiopathological responses to the surgical
procedure and allowed to identify MCP-1 as a key molecular
mediator involved in the wound healing process after PRK.
Moreover, the present study, based on the application of a
multiplex-array approach in the PRKmodel of corneal regen-
eration, certainly contributes to the improvements in the
development of biomarker profiles for other ocular surface
diseases requiring monitoring of the pathology development
as well as monitoring after surgery.
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